Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Gains Positive Regulatory Nods For Dulera And Brinavess

Executive Summary

Merck received two pieces of good news from regulatory authorities within a few days - first an FDA approval for its asthma drug Dulera, then a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for its intravenous atrial fibrillation drug Brinavess

You may also be interested in...



Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation

First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.

Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation

First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.

LABA Safety Studies, REMS Are Next Topics For Sponsors, FDA After Relabeling

Discussions about how best to study the safety of long-acting beta agonists are ready to resume now that FDA has issued a revised label for the drug class

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS052374

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel